Table 4 Results of linear regression models and Cohen’s d for efficacy outcomes at post-treatment (t1) and 6-month follow-up (t2) based on ITT analyses

Outcome

PHQ-ADS

0.20 [-0.47; 0.88]

0.30 [-0.52; 1.10]

-0.55 [-1.17; 0.07]

-0.36 [-1.18; 0.48]

CODI*

-0.18 [-0.83; 0.48}

-0.70 [-1.54; 0.16]

0.15 [-0.44; 0.74]

-0.37 [-1.21; 0.49]

VAS*

0.24 [-0.52; 1.00]

0.31 [-0.51; 1.11]

0.22 [-0.63; 1.07]

0.23 [-0.62; 1.07]

GSE*

0.11 [-0.39; 0.61]

-0.32 [-1.13; 0.50]

0.15 [-0.55; 0.85]

-0.34 [-1.19; 0.52]

SRGS*

-0.19 [-0.74; 0.37]

0.24 [-0.57; 1.04]

0.29 [-0.33; 0.90]

0.78 [-0.14; 1.66]

CATS

-0.36 [-0.97; 0.26]

-0.20 ([-1.00; 0.61]

-0.67 [-1.26; -0.08]

-0.45 [-1.3; 0.42]

AUDIT-C

0.09 [-0.30; 0.48]

0.20 [-0.61; 1.00]

0.04 [-0.64; 0.71]

-0.14 [-0.98; 0.70]

BSSS*

0.04 [-0.69; 0.69]

0.18 [-0.63; 0.99]

-0.29 [-1.13; 0.56]

-0.20 [-1.04; 0.65]

IUES

0.10 [-0.58; 0.78]

0.05 [-0.76; 0.85]

-0.22 [-0.77; 0.33]

-0.18 [-1.02; 0.67]

BADS*

-0.10 [-0.77; 0.57]

-0.53 [-1.35; 0.31]

0.64 [-0.02; 1.30]

0.12 [-0.73; 0.96]

ATQ-R

0.39 [-0.21; 0.99]

0.38 [-0.45; 1.19]

0.06 [-0.54; 0.70]

0.09 [-0.76; 0.92]